1. Acierno, P. M., et al. 2006. Preservation of functional virus-specific memory CD8 T lymphocytes in vaccinated, simian human immunodeficiency virus- infected rhesus monkeys. J. Immunol. 176:5338–5345.
2. Agarwal, P., et al. 2009. Gene regulation and chromatin remodeling by IL-12 and type I IFN in programming for CD8 T cell effector function and memory. J. Immunol. 183:1695–1704.
3. Bachmann, M. F., P. Wolint, K. Schwarz, and A. Oxenius. 2005. Recall proliferation potential of memory CD8 T cells and antiviral protection. J. Immunol. 175:4677–4685.
4. Belz, G. T., and A. Kallies. 2010. Effector and memory CD8 T cell differentiation: toward a molecular understanding of fate determination. Curr. Opin. Immunol. 22:279–285.
5. Boscardin, S. B., S. S. Kinoshita, A. E. Fujimura, and M. M. Rodrigues. 2003. Immunization with cDNA expressed by amastigotes of Trypanosoma cruzi elicits protective immune response against experimental infection. Infect. Immun. 71:2744–2757.
6. Bustamante, J. M., L. M. Bixby, and R. L. Tarleton. 2008. Drug-induced cure drives conversion to a stable and protective CD8 T central memory response in chronic Chagas disease. Nat. Med. 14:542–550.
7. Cardillo, F., J. C. Voltarelli, S. G. Reed, and J. S. Silva. 1996. Regulation of Trypanosoma cruzi infection in mice by gamma interferon and interleukin 10: role of NK cells. Infect. Immun. 64:128–134.
8. Casimiro, D. R., et al. 2003. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 77:6305–6313.
9. Casimiro, D. R., et al. 2005. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag. J. Virol. 79:15547–15555.
10. Curtsinger, J. M., and M. F. Mescher. 2010. Inflammatory cytokines as a third signal for T cell activation. Curr. Opin. Immunol. 22:333–340.
11. Da Fonseca, F., and B. Moss. 2003. Poxvirus DNA topoisomerase knockout mutant exhibits decreased infectivity associated with reduced early transcrip- tion. Proc. Natl. Acad. Sci. U. S. A. 100:11291–11296.
12. Dalton, D. K., et al. 1993. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 259:1739–1742.
13. De Alencar, B. C., et al. 2009. Perforin and gamma interferon expression are required for CD4 and CD8 T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination. Infect. Immun. 77:4383–4395.
14. Dudani, R., K. Murali-Krishna, L. Krishnan, and S. Sad. 2008. IFN-gamma induces the erosion of preexisting CD8 T cell memory during infection with a heterologous intracellular bacterium. J. Immunol. 181:1700–1709.
15. Duthie, M. S., et al. 2002. During Trypanosoma cruzi infection CD1d-re- stricted NK T cells limit parasitemia and augment the antibody response to a glycophosphoinositol-modified surface protein. Infect. Immun. 70:36–48.
16. Finn, J. D., et al. 2009. Persistence of transgene expression influences CD8 T-cell expansion and maintenance following immunization with recombinant adenovirus. J. Virol. 83:12027–12036.
17. Freel, S. A., et al. 2010. Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination. J. Virol. 84:4998–5006.
18. Geisbert, T. W., et al. 2010. Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates. J. Virol. 84:10386–10394.
19. Gilbert, S. C., et al. 2002. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunization regimes. Vaccine 20: 1039–1045.
20. Hensley, L. E., et al. 2010. Demonstration of cross-protective vaccine immunity against an emerging pathogenic ebolavirus species. PLoS Pathog. 6:e1000904.
21. Hikono, H., et al. 2007. Activation phenotype, rather than central- or effec- tor-memory phenotype, predicts the recall efficacy of memory CD8 T cells. J. Exp. Med. 204:1625–1636.
22. Hill, A. V., et al. 2010. Prime-boost vectored malaria vaccines: progress and prospects. Hum. Vaccin. 6:78–83.
23. Hoft, D. F., and C. S. Eickhoff. 2005. Type 1 immunity provides both optimal mucosal and systemic protection against a mucosally invasive, intracellular pathogen. Infect. Immun. 73:4934–4940.
24. Huster, K. M., et al. 2009. Cutting edge: memory CD8 T cell compartment grows in size with immunological experience but nevertheless can lose function. J. Immunol. 183:6898–6902.
25. Jameson, S. C., and D. Masopust. 2009. Diversity in T cell memory: an embarrassment of riches. Immunity 31:859–871.
26. Jaoko, W., et al. 2010. Safety and immunogenicity study of multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS One 5:e12873.
27. Klebanoff, C. A., et al. 2005. Central memory self/tumor-reactive CD8 T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl. Acad. Sci. U. S. A. 102:9571–9576.
28. Koup, R. A., et al. 2010. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One 5:e9015.
29. Letvin, N. L., et al. 2006. Preserved CD4 central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 312:1530–1533.
30. Lieke, T., S. E. Graefe, U. Klauenberg, B. Fleischer, and T. Jacobs. 2004. NK cells contribute to the control of Trypanosoma cruzi infection by killing free parasites by perforin-independent mechanisms. Infect. Immun. 72:6817– 6825.
31. Lu, S. 2009. Heterologous prime-boost vaccination. Curr. Opin. Immunol. 21:346–351.
32. Machado, A. V., et al. 2006. Long-term protective immunity induced against Trypanosoma cruzi infection after vaccination with recombinant adenoviruses encoding amastigote surface protein-2 and trans-sialidase. Hum. Gene Ther. 17:898–908.
33. Magram, J., et al. 1996. IL-12-deficient mice are defective in IFN produc- tion and type 1 cytokine responses. Immunity 4:471–481.
34. Marques, E. T., Jr., et al. 2003. HIV-1 p55Gag encoded in the lysosome- associated membrane protein-1 as a DNA plasmid vaccine chimera is highly expressed, traffics to the major histocompatibility class II compartment, and elicits enhanced immune responses. J. Biol. Chem. 278:37926–37936.
35. Masopust, D., S. J. Ha, V. Vezys, and R. Ahmed. 2006. Stimulation history dictates memory CD8 T cell phenotype: implications for prime-boost vaccination. J. Immunol. 177:831–839.
36. Obar, J. J., and L. Lefran  ̧ois. 2010. Early events governing memory CD8 T-cell differentiation. Int. Immunol. 22:619–625.
37. Pearce, E. L., and H. Shen. 2007. Generation of CD8 T cell memory is regulated by IL-12. J. Immunol. 179:2074–2081.
38. Radosevi  ́, K., A. Rodriguez, A. Lemckert, and J. Goudsmit. 2009. Heterologous prime-boost vaccinations for poverty-related diseases: advantages and future prospects. Expert Rev. Vaccines 8:577–592.